Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses
Authors' conclusion
This paper presents a dose-informed methodological framework for future evidence syntheses in obesity pharmacotherapy, supporting comparative evaluation and contextual positioning of next-generation OMMs.
Study context
- Population
- Randomised Phase 1–4 trials in adults with overweight or obesity, with or without T2D
- Comparison
- Approved and investigational obesity management medications
- Outcome
- Percentage total body weight loss
- Follow-up
- ≈24-26 weeks
Methodological detailsPRISMA 2020, PRISMA-NMA and PRISMA-P, class-specific network meta-analyses, dose-informed treatment nodes (molecule-dose combinations), RoB 2 and CINeMA
- PRISMA 2020, PRISMA-NMA and PRISMA-P
- Class-specific network meta-analyses
- Dose-informed treatment nodes (molecule-dose combinations)
- RoB 2 and CINeMA
Pooled result
As reported in the abstract
Candidate interventions identified
- Investigational obesity molecules that completed at least Phase 1, grouped into 13 major mechanistic classes
- 40
- Approved therapies for obesity
- nine
- Total candidate molecules for future class-specific network meta-analyses
- 49
Original publication
Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses. Diabetes Obes Metab. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →